These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32607912)

  • 21. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
    Ahmad A; Uddin S; Steinhoff M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput sequencing of the immune repertoire in oncology: Applications for clinical diagnosis, monitoring, and immunotherapies.
    Ye B; Smerin D; Gao Q; Kang C; Xiong X
    Cancer Lett; 2018 Mar; 416():42-56. PubMed ID: 29247824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation.
    Pantin J; Battiwalla M
    Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging CAR landscape for cancer immunotherapy.
    Lim FLWI; Ang SO
    Biochem Pharmacol; 2020 Aug; 178():114051. PubMed ID: 32446888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
    Cifaldi L; Di Santo J; Olive D
    Front Immunol; 2020; 11():1132. PubMed ID: 32612604
    [No Abstract]   [Full Text] [Related]  

  • 29. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR T-Cell Therapy: Update on the State of the Science.
    Lamprecht M; Dansereau C
    Clin J Oncol Nurs; 2019 Apr; 23(2):6-12. PubMed ID: 30880819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Mol Cancer Ther; 2020 Dec; 19(12):2409-2421. PubMed ID: 33087511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoptosis: a
    Lee YG; Yang N; Chun I; Porazzi P; Carturan A; Paruzzo L; Sauter CT; Guruprasad P; Pajarillo R; Ruella M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37055217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
    Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
    Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
    Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective.
    Mahmood S; Upreti D; Sow I; Amari A; Nandagopal S; Kung SK
    Immunotherapy; 2015; 7(3):301-8. PubMed ID: 25804481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.
    Hashemi V; Farhadi S; Ghasemi Chaleshtari M; Seashore-Ludlow B; Masjedi A; Hojjat-Farsangi M; Namdar A; Ajjoolabady A; Mohammadi H; Ghalamfarsa G; Jadidi-Niaragh F
    Int Immunopharmacol; 2020 Jun; 83():106446. PubMed ID: 32244048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges.
    Iyer RK; Bowles PA; Kim H; Dulgar-Tulloch A
    Front Med (Lausanne); 2018; 5():150. PubMed ID: 29876351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment.
    Rodríguez Pérez Á; Campillo-Davo D; Van Tendeloo VFI; Benítez-Ribas D
    Clin Transl Oncol; 2020 Nov; 22(11):1923-1937. PubMed ID: 32266674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.